Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
作者:
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环孢菌素类(Cyclosporins);阿糖胞苷(Cytarabine);无病生存(Disease-Free Survival);依托泊甙(Etoposide);女(雌)性(Female);基因, MDR(Genes, MDR);人类(Humans);Logistic模型(Logistic Models);男(雄)性(Male);中年人(Middle Aged);米托蒽醌(Mitoxantrone);多元分析(Multivariate Analysis);骨髓增生异常综合征(Myelodysplastic Syndromes);存活率分析(Survival Analysis);美国(United States)
DOI
10.1200/JCO.2004.07.048
PMID
15020609
发布时间
2024-06-10
- 浏览120

Journal of clinical oncology
1078-86页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文